Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Banco Santander SA (SAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Banco Santander SA — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Banco Santander SA trades at $13.75 (market cap $197.91B). The key difference: Banco Santander SA is far larger — about 5× Alnylam Pharmaceuticals, Inc.'s market cap, and Banco Santander SA pays a 2.01% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | SAN | |
|---|---|---|
Market Cap | $39.89B | $197.91B |
Sector | Health | Financials |
52-Week High | $491.22 | $14.37 |
52-Week Low | $278.09 | $8.31 |
Enterprise Value | $38.15B | — |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Banco Santander (SAN) trades at $13.87, up 0.58% today, with a bullish technical signal from moving averages. The company reported $14.10B net income for 2025 with a 23.49% margin, though recent quarterly EPS results missed expectations. Analyst consensus is 64% buy, supported by news of Santander becoming Spain's most valuable company and its AI-driven efficiency initiatives.
Outlook is cautiously optimistic with strong profitability and strategic acquisitions, but risks include consecutive EPS misses, a significant net cash outflow trend, and regulatory scrutiny in Spain. The stock's valuation appears reasonable with a P/E of 13.78, offering potential upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
